GlassScriptPhysician profile
Sylvia Orandi
NPI 1437503794
$3,075.62
in general payments reported to CMS, 2019-2025
38 companies · $31.70 in 2025
The $31.70 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $666 · 2022: $667 · 2023: $854 · 2024: $857 · 2025: $31.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,743.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $374.81 | 2022-2024 | Austedo Xr, Austedo |
| Abbvie INC. | $250.81 | 2022-2025 | |
| Astellas Pharma US INC | $216.60 | 2021-2024 | Veozah, Myrbetriq |
| Abbott Laboratories | $191.66 | 2021-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $167.16 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $146.96 | 2023-2024 | Rexulti |
| Glaxosmithkline, LLC. | $137.97 | 2021-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Eisai INC. | $120.94 | 2021-2024 | |
| Novo Nordisk INC | $114.15 | 2021-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $111.37 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $109.02 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $103.46 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.15 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $86.59 | 2021-2024 | Airsupra, Breztri |
| Amarin Pharma, INC. | $79.33 | 2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $78.68 | 2022-2024 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.81 | 2021-2024 | Xifaxan, Relistor |
| Amgen INC. | $48.28 | 2021-2024 | Krystexxa, Repatha, Otezla |
| Lilly USA, LLC | $46.32 | 2021-2023 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.64 | 2024 | Jardiance |
| Sumitomo Pharma America, INC. | $42.33 | 2023 | Gemtesa |
| Nestle Healthcare Nutrition INC. | $41.05 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $39.57 | 2021 | |
| Janssen Pharmaceuticals, INC | $37.07 | 2022-2024 | Spravato |
| Urovant Sciences INC | $36.66 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $36.45 | 2021 | |
| Boston Scientific Corporation | $33.10 | 2024 | |
| Neurocrine Biosciences, INC. | $26.57 | 2022 | |
| Vivus LLC | $25.90 | 2021-2024 | Qsymia |
| Sunovion Pharmaceuticals INC. | $25.42 | 2022 | |
| Silk Road Medical, INC. | $24.27 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Sanofi-Aventis U.S. LLC | $20.80 | 2024 | |
| Endo Pharmaceuticals INC. | $20.43 | 2021 | |
| Radius Health, INC. | $18.96 | 2024 | |
| Adlon Therapeutics L.P. | $16.47 | 2021 | |
| Solventum Corporation | $14.64 | 2025 | Activ.A.C. |
| Sanofi Pasteur INC. | $14.39 | 2021 | |
| Phadia US INC. | $12.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sylvia Orandi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.